此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

1阶段AAV基因治疗试验,评估RP-A701在患有BAG3扩张性心肌病的受试者中的安全性和初步疗效

2026年9月30日 更新者:Rocket Pharmaceuticals Inc.

A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human BCL2-associated Athanogene 3 (BAG3) Gene Coding Sequence (RP-A701) in Subjects With Dilated Cardiomyopathy Arising From Pathogenic BAG3 Variants (BAG3-DCM)

This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.

研究概览

研究类型

介入性

注册 (估计的)

8

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • San Diego、California、美国、92037
        • 招聘中
        • University of California, San Diego
        • 首席研究员:
          • Barry Greenberg, MD
        • 接触:
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic
        • 首席研究员:
          • John Giudicessi, MD, PhD
        • 接触:
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 招聘中
        • Medical University of South Carolina
        • 首席研究员:
          • Daniel Judge, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Subjects are eligible for inclusion into the study only if all the following criteria apply:

  1. Male or female between 18 and 65 years of age at the time of signing the informed consent

  2. Capable of and willing to provide signed informed consent

  3. Clinical diagnosis of DCM defined as and requiring each of the following:

    1. Mild to moderate systolic dysfunction (LVEF ≥ 25% and ≤ 45%) by echocardiography or CMR performed within 3 months of enrollment.
    2. Absence of severe coronary artery disease (>70% stenosis) or active myocardial ischemia as the etiology of LV systolic dysfunction
    3. Absence of uncontrolled hypertension, significant cardiac valve disease (i.e., greater than moderate in severity), infiltrative disorder, or systemic disease known to cause cardiomyopathy.
  4. Documentation of a pathogenic or likely pathogenic variant in BAG3

  5. History of ICD implantation ≥ 3 months prior to enrollment

  6. NYHA Class II or III HF symptoms with stable HF therapeutic guideline-directed medical regimen for 30 days prior to enrollment

Exclusion Criteria:

  1. CV disease that may be related to a genetic etiology other than a BAG3 pathogenic or likely pathogenic variant.
  2. Previous participation in a study of gene transfer or gene editing.
  3. I.V. inotropic, vasodilator, or diuretic therapy ≤ 30 days prior to enrollment.
  4. History of intracardiac thrombosis or arterial thromboembolic events
  5. Severe RV dysfunction assessed by echocardiogram or CMR ≤ 12 months prior to screening
  6. LVEF < 25% by echocardiogram or CMR at ≤ 3 months prior to screening
  7. NYHA Class I or IV HF

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Single ascending dose of RP-A701 in up to 2 consecutive cohorts

Participants will receive a single intravenous dose of RP-A701 on Day 0 and will be followed for up to two years

One-time treatment with a single ascending dose

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Treatment-emergent Adverse Events (TEAE)
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Number of participants with Adverse Events following a single IV dose of RP-A701

Baseline up to End of Study (up to 24 months post-infusion)
Incidence of Treatment-emergent Serious Adverse Events (SAE).
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Number of participants with Serious Adverse Events (SAE) following a single IV dose of RP-A701

Baseline up to End of Study (up to 24 months post-infusion)
Incidence of Dose Limiting Toxicities (DLT).
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Number of participants with Dose Limiting Toxicities (DLT) following a single IV dose of RP-A701

Baseline up to End of Study (up to 24 months post-infusion)

次要结果测量

结果测量
措施说明
大体时间
To assess the impact of RP-A701 on features of cardiovascular function.
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Change in measures of LV systolic function, including LV ejection fraction (LVEF), LV global longitudinal strain.

Baseline up to End of Study (up to 24 months post-infusion)
To assess the impact of RP-A701 on features of cardiovascular function.
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Change in peak oxygen consumption (VO2) or ventilatory efficiency (VE/VCO2 slope) by cardiopulmonary exercise test (CPET)

Baseline up to End of Study (up to 24 months post-infusion)
To assess the impact of RP-A701 on features of cardiovascular function.
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Change in 6-minute walk distance.

Baseline up to End of Study (up to 24 months post-infusion)
To assess the extent of RP-A701 transduction and protein expression.
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Change in BAG3 myocardial protein expression

Baseline up to End of Study (up to 24 months post-infusion)
To assess the impact of RP-A701 on features of heart failure (HF).
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Change in symptoms of HF assessed by New York Heart Association (NYHA) class.

Baseline up to End of Study (up to 24 months post-infusion)
To assess the impact of RP-A701 on quality of life.
大体时间:Baseline up to End of Study (up to 24 months post-infusion)

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ-12) Overall Summary Score.

Baseline up to End of Study (up to 24 months post-infusion)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月17日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2029年6月1日

研究注册日期

首次提交

2025年7月25日

首先提交符合 QC 标准的

2025年8月20日

首次发布 (实际的)

2025年8月22日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅